Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma — Stella

Home/Relapsed or Refractory Multiple Myeloma/YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Relapsed or Refractory Multiple Myeloma trials

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

Key details

Phase

Early testing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

China Immunotech (Beijing) Biotechnology Co., Ltd.

Enrollment target

~12 participants

Started

June 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.